Onera Health

"Bringing PSG Home. The first self-applied, no-wire Polysomnography solution." [1]

Where it wins

• Clinicians can order a gold-standard sleep study (PSG) without requiring patients to visit a lab or sleep center, removing the archaic, inconvenient, and expensive barriers of traditional diagnostics [1].
• The Onera Sleep Test System (STS) is a patch-based, no-wire sensor system that captures cardiovascular, respiratory, and brain function signals, designed for minimal sleep disturbance during recording [1].
• Onera offers a "PSG-as-a-service" model that combines the hardware with a cloud-based Digital Health Platform, allowing for end-to-end sleep diagnostics and monitoring anywhere and anytime [1].
• The system delivers EDF files via the cloud, which are compatible with commonly used sleep analysis software, integrating seamlessly into existing clinical workflows [1].

Credibility: The Onera STS is a Class IIa medical device, CE marked under MDD 93/42/EEC in Europe, and FDA 510(k) cleared for use in the United States [1].

• Hardware-Software Integration: Onera sells a complete diagnostic solution by combining its proprietary no-wire sensor hardware (STS) with a cloud-based Digital Health Platform for data processing and reporting [1].
• Service-Based Scaling: The "PSG-as-a-service" model allows Onera to scale its diagnostics without requiring clinics to invest in expensive infrastructure, charging a fixed fee per study instead [1].
• Component Supply: Beyond end-user devices, Onera develops and supplies the Onera ONE010 biomedical sensor chip, enabling other manufacturers to build wearable health devices [2].
• Regulatory Moat: By securing CE marking and FDA 510(k) clearance, Onera positions its hardware as a Class IIa medical device, creating a barrier to entry for non-compliant competitors [1].

• Traditional Sleep Labs: Offer in-lab PSG but are limited by high costs, low patient compliance, and geographic constraints [1].
• Consumer Sleep Trackers: Devices like Oura or Whoop provide sleep data but lack clinical-grade accuracy and regulatory approval for diagnostics [1].
• Other Home PSG Providers: Competitors in the home sleep apnea testing (HSAT) space, but Onera differentiates with a full PSG signal set and no-wire design [1].
• Wearable Health Chip Suppliers: Companies providing biosensor chips, but Onera's ONE010 is specialized for medical-grade ExG and bioimpedance signals [2].

Differentiators: Onera's combination of a no-wire, self-applied clinical-grade PSG system with a cloud-based service model and regulatory approvals sets it apart from both consumer wearables and traditional lab-based diagnostics [1].

• Inconvenience of Traditional PSG: Patients find in-lab sleep studies intimidating, archaic, and inconvenient, leading to low compliance and delayed diagnoses [1].
• High Costs for Providers: Sleep labs require significant upfront investment in infrastructure and staffing, making diagnostics expensive for healthcare systems [1].
• Sleep Disorder Prevalence: 1 in 5 people struggle with sleep issues like insomnia or sleep apnea, yet many go undiagnosed due to access barriers [1].
• Data Fragmentation: Clinicians often struggle with integrating sleep data into existing workflows, requiring compatible software and seamless data delivery [1].

Onera's PSG-as-a-service model directly addresses the scalability crisis in sleep medicine by shifting diagnostics from capital-intensive labs to decentralized, home-based settings. The regulatory moat (FDA/CE) is a critical asset that prevents low-cost, non-compliant competitors from eroding market share. The main risk is reimbursement uncertainty; without clear payer pathways, adoption may stall despite clinical efficacy. The next signal to watch is the expansion of analysis and reporting services into new geographies, which would indicate scaling beyond hardware sales into a recurring service revenue stream.

Onera should prioritize securing explicit reimbursement codes from major payers (e.g., CMS in the US) to de-risk the PSG-as-a-service model for clinics. Expanding the ONE010 chip's marketing to non-sleep wearable applications (e.g., cardiac monitoring, stress tracking) could diversify revenue and reduce reliance on the sleep diagnostics market. Developing a patient-facing app that provides real-time sleep insights could improve engagement and create a direct-to-consumer channel, complementing the B2B clinical model. Forming strategic partnerships with telehealth platforms to embed Onera's PSG solution directly into their workflows would accelerate distribution and reduce customer acquisition costs.